Saving Minds
The future of medicine for Alzheimer’s and Parkinson’s diseases
4 years ago

Episode 11 – What Is TDP43 and What Are We Going to Do About It?

Elliot is back to discuss the TDP43 protein, which has been implicated in the development of a recently discovered form of dementia as well as ALS. Shanti and Elliot talk about why TDP43 is important, and the efforts to neutralize the misfolded...

Elliot is back to discuss the TDP43 protein, which has been implicated in the development of a recently discovered form of dementia as well as ALS. Shanti and Elliot talk about why TDP43 is important, and the efforts to neutralize the misfolded protein in the brain before it can destroy brain cells.

Read more…
4 years ago

Episode 7 – Dr. Johanne Kaplan on the Importance of Selectivity

Shanti is joined by Dr. Johanne Kaplan, the Chief Development Officer at ProMIS Neurosciences. The two discuss Dr. Kaplan's career, and the current challenges researchers must tackle as they continue their search for a way to stop Alzheimer's disease....

Shanti is joined by Dr. Johanne Kaplan, the Chief Development Officer at ProMIS Neurosciences. The two discuss Dr. Kaplan's career, and the current challenges researchers must tackle as they continue their search for a way to stop Alzheimer's disease. The two also discuss Dr. Kaplan's recent paper on the importance of selectivity in drug development for Alzheimer's.

Read more…
4 years ago

Episode 6 – The "One-Two Punch" of Abeta and Tau

Toxic tau and amyloid-beta are the two most validated drug targets for an Alzheimers disease therapy. Elliot and Shanti discuss tau, its role as a root cause of Alzheimer's disease and its involvement in 80 other diseases known as tauopathies.

Toxic tau and amyloid-beta are the two most validated drug targets for an Alzheimers disease therapy. Elliot and Shanti discuss tau, its role as a root cause of Alzheimer's disease and its involvement in 80 other diseases known as tauopathies.

Read more…
4 years ago

Episode 5 – Major Late-stage Alzheimer's Failures

Dr. Goldstein and Shanti breakdown the news of the week. This week they discuss two major late-stage failures for promising Alzheimer's drugs, a new syndrome that is similar to Alzheimer's, and some important biomarker developments.

Dr. Goldstein and Shanti breakdown the news of the week. This week they discuss two major late-stage failures for promising Alzheimer's drugs, a new syndrome that is similar to Alzheimer's, and some important biomarker developments.

Read more…
5 years ago

Episode 4 – How do Biomarkers Work?

This is part two of our exploration of biomarkers. Elliot and Shanti discuss how biomarkers work and how they will play a critical role in the future of drug development for the various brain-wasting diseases.

This is part two of our exploration of biomarkers. Elliot and Shanti discuss how biomarkers work and how they will play a critical role in the future of drug development for the various brain-wasting diseases.

Read more…
5 years ago

Episode 3 – Why Biomarkers Matter

Dr. Goldstein and Shanti discuss why biomarkers are becoming increasingly important in the medical community. They also discuss how biomarkers are uniquely important in the quest for a cure for Alzheimer's.

Dr. Goldstein and Shanti discuss why biomarkers are becoming increasingly important in the medical community. They also discuss how biomarkers are uniquely important in the quest for a cure for Alzheimer's.

Read more…
5 years ago

Episode 2 – Understanding Parkinson's Disease

This week Dr. Goldstein and Shanti discuss Parkinson's disease. They discuss the underlying cause of Parkinson's, treatment options, side effects and the connection between Parkinson's and Alzheimer's

This week Dr. Goldstein and Shanti discuss Parkinson's disease. They discuss the underlying cause of Parkinson's, treatment options, side effects and the connection between Parkinson's and Alzheimer's

Read more…